by Rod Raynovich | Nov 22, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every...
by Rod Raynovich | Nov 18, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with castration-resistant prostate cancer (CRPC) achieving either partial or complete...
by Rod Raynovich | Nov 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics reported revenues of $4.1M for Q3 2010 ended Sep 30 a decrease of 9% or $500k compared to the same period of 2009. Excluding revenues of $1.3M attributed to machine production of the 2009 H1N1 Flu pandemic, revenues grew 29%.Unit sales increased to 144...
by Rod Raynovich | Nov 8, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is a leader in automated blood...
by Rod Raynovich | Oct 29, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Abaxis (ABAX) beat estimates with reported Q3 Revenues of $35.3M/$0.17 up 17% over last year’s comparable quarter. Cash position is $100.6M up from $87.6M last year’s Q3. March ’11 Fiscal Year estimates are $143M and $0.72/sh. Shares are up 0.97%...
by Rod Raynovich | Oct 27, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Timing is everything and Pacific Biosciences(PACB) took advantage of a good year for biotech stocks, better earnings for tools and Dx companies and a rebounding IPO market. Pacific Biosciences raised $200M($16) at the midpoint of the expected range and shares advanced...
by Rod Raynovich | Oct 20, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Risk is on today due to a weak dollar and that is usually good for Life Science stocks.MidCap biotechs are mainly green despite bad news from Amylin (AMLN) $11.35 down 44%, and partner Alkermes (ALKS) $10.91 down 24.75% a setback on their long- acting drug for...
by Rod Raynovich | Oct 6, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Stock is down over 18% at 3p near $16.5 on 7M shares A “Pure Play “Immunohematology Diagnostic Company Immucor announced Fiscal Q1 2011 results yesterday with a revenue shortfall of (9%) on traditional reagents $49.621M vs $54.719M in Fiscal 2010. Total...
by Rod Raynovich | Oct 5, 2010 | 2024-25 Life Science Portfolios, BIOgraph
2010 Original Price % Ret. P Price % Recomm 3/29/10 Q2 12/1/10 Ret. Abaxis ABAX 2/2/09 15 79 21.2 27.86 85 CardioV.Sys. CSII 11/5/10 7.15 8.65 21 Celera CRA 3/28/10 7 6.49 5.66 -19 GenProbe GPRO 2/2/09 45 7 46.3 52.77 17 Illumina ILMN 2/2/09 29 35 43.1 61.79 113...
by Rod Raynovich | Oct 4, 2010 | 2024-25 Life Science Portfolios, BIOgraph
2010 Price Original P Price % Ret 7/2/10 Recomm 12/1/10 Alexion ALXN 50.45 2/2/09 35 76.24 117 Ardea Biosci RDEA 19.5 2/2/09 12 22.26 85 Amgen AMGN 51.7 2/2/09 55 53.52 -5 Biogen BIIB 49.42 2/2/09 49 65.37 33 Cephalon CEPH 55.95 2/2/09 77 64.26 -16.5 Cubist CBST 20.7...
